Freddie Mac CFO Discusses First Quarter 2025 Financial and Business Results
Remarks of James WhitlingerIntroductionGood morning and thank you for joining our call to review Freddie Mac’s first quarter performance.Let’s start...
Remarks of James WhitlingerIntroductionGood morning and thank you for joining our call to review Freddie Mac’s first quarter performance.Let’s start...
Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3...
Third Quarter Financial Highlights: Total revenues decreased $17.4 million year over year to $448.8 millionConstruction Equipment and Material Handling revenues...
Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30...
--Completed End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA); on track to initiate Phase 3 clinical...